Generic placeholder image

Current Gene Therapy

Editor-in-Chief

ISSN (Print): 1566-5232
ISSN (Online): 1875-5631

General Research Article

Recombinant Adeno-associated Virus 9-mediated Expression of Kallistatin Suppresses Lung Tumor Growth in Mice

Author(s): Weihong Qu*, Jianguo Zhao, Yaqing Wu, Ruian Xu* and Shaowu Liu

Volume 21 , Issue 1 , 2021

Published on: 11 November, 2020

Page: [72 - 80] Pages: 9

DOI: 10.2174/1566523220999201111194257

Price: $65

Abstract

Background: Lung cancer remains the most common cause of cancer-related deaths in China and worldwide. Traditional surgery and chemotherapy do not offer an effective cure, although gene therapy may be a promising future alternative. Kallistatin (Kal) is an endogenous inhibitor of angiogenesis and tumorigenesis. Recombinant adeno-associated virus (rAAV) is considered the most promising vector for gene therapy of many diseases due to persistent and long-term transgenic expression.

Objective: The aim of this study was to investigate whether rAAV9-Kal inhibited NCI-H446 subcutaneous xenograft tumor growth in mice.

Methods: The subcutaneous xenograft mode was induced by subcutaneous injection of 2×107 H446 cells into the dorsal skin of BALB/c nude mice. The mice were administered with ssrAAV9-Kal (single- stranded rAAV9) or dsrAAV9-Kal (double-stranded rAAV9) by intraperitoneal injection (I.P.). Tumor microvessel density (MVD) was examined by anti-CD34 staining to evaluate tumor angiogenesis.

Results: Compared with the PBS (blank control) group, tumor growth in the high-dose ssrAAV9-Kal group was inhibited by 40% by day 49, and the MVD of tumor tissues was significantly decreased.

Conclusion: The results indicate that this therapeutic strategy is a promising approach for clinical cancer therapy and implicate rAAV9-Kal as a candidate for gene therapy of lung cancer.

Keywords: Recombinant adeno-associated virus, kallistatin, subcutaneous xenograft tumor growth, anti-angiogenic, lung cancer, gene therapy.

Graphical Abstract
[1]
Latteyer S, Christoph S, Theurer S, et al. Thyroxine promotes lung cancer growth in an orthotopic mouse model. Endocr Relat Cancer 2019; 26(6): 565-74.
[http://dx.doi.org/10.1530/ERC-18-0353] [PMID: 30893642]
[2]
Dimitrova N, Gocheva V, Bhutkar A, et al. Stromal expression of mir-143/145 promotes neoangiogenesis in lung cancer development. Cancer Discov 2016; 6(2): 188-201.
[http://dx.doi.org/10.1158/2159-8290.CD-15-0854] [PMID: 26586766]
[3]
Shukla NA, Yan MN, Hanna N. The story of angiogenesis inhibitors in non-small-cell lung cancer: The past, present, and future. Clin Lung Cancer 2020; 21(4): 308-13.
[http://dx.doi.org/10.1016/j.cllc.2020.02.024] [PMID: 32291211]
[4]
Saravanan S, Vimalraj S, Pavani K, et al. Intussusceptive angiogenesis as a key therapeutic target for cancer therapy. Life Sci 2020; 252117670
[http://dx.doi.org/10.1016/j.lfs.2020.117670] [PMID: 32298741]
[5]
Liu ZL, Zhu WR, Zhou WC, et al. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis. J Integr Med 2014; 12(4): 346-58.
[http://dx.doi.org/10.1016/S2095-4964(14)60034-0] [PMID: 25074884]
[6]
Wang G, Zou J, Yu X, Yin S, Tang C. The antiatherogenic function of kallistatin and its potential mechanism. Acta Biochim Biophys Sin (Shanghai) 2020; 52(6): 583-9.
[http://dx.doi.org/10.1093/abbs/gmaa035] [PMID: 32393963]
[7]
Zheng CN, Duan XW, Jia DF, et al. Anti-inflammatory effect of recombinant human kallistatin in ulcerative colitis of mice. Yao Xue Xue Bao 2016; 51(7): 1077-82.
[PMID: 29897181]
[8]
Jia D, Zheng C, Feng J, Zou J, Diao Y. Plasmid mediated kallistain gene expression via intramuscular electroporation delivery in vivo for treatment of NCI-H446 subcutaneous xenograft tumor. Pak J Pharm Sci 2014; 27(3)(Suppl.): 633-6.
[PMID: 24816705]
[9]
Guo Y, Li P, Bledsoe G, Yang ZR, Chao L, Chao J. Kallistatin inhibits TGF-β-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression. Exp Cell Res 2015; 337(1): 103-10.
[http://dx.doi.org/10.1016/j.yexcr.2015.06.021] [PMID: 26156753]
[10]
Huang KF, Yang HY, Xing YM, Lin JS, Diao Y. Recombinant human kallistatin inhibits angiogenesis by blocking VEGF signaling pathway. J Cell Biochem 2014; 115(3): 575-84.
[http://dx.doi.org/10.1002/jcb.24693] [PMID: 24129914]
[11]
Lisowski L, Dane AP, Chu K, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 2014; 506(7488): 382-6.
[http://dx.doi.org/10.1038/nature12875] [PMID: 24390344]
[12]
Walia JS, Altaleb N, Bello A, et al. Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates. Mol Ther 2015; 23(3): 414-22.
[http://dx.doi.org/10.1038/mt.2014.240] [PMID: 25515709]
[13]
Tse LY, Sun X, Jiang H, et al. Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. J Gene Med 2008; 10(5): 508-17.
[http://dx.doi.org/10.1002/jgm.1180] [PMID: 18338836]
[14]
Qu G, Bahr-Davidson J, Prado J, et al. Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J Virol Methods 2007; 140(1-2): 183-92.
[http://dx.doi.org/10.1016/j.jviromet.2006.11.019] [PMID: 17196264]
[15]
Qu W, Wang M, Wu Y, et al. Calcium-ion-modulated ceramic hydroxyapatite resin for the scalable purification of recombinant adeno-associated virus serotype 9. J Chromatogr B 2015; 990: 12-5.
[http://dx.doi.org/10.1016/j.jchromb.2015.03.003] [PMID: 25841202]
[16]
Ayuso E, Mingozzi F, Montane J, et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther 2010; 17(4): 503-10.
[http://dx.doi.org/10.1038/gt.2009.157] [PMID: 19956269]
[17]
Lu L, Yang Z, Zhu B, et al. Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity. Cancer Lett 2007; 257(1): 97-106.
[http://dx.doi.org/10.1016/j.canlet.2007.07.008] [PMID: 17714861]
[18]
Wang CR, Chen SY, Wu CL, et al. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 2005; 52(4): 1319-24.
[http://dx.doi.org/10.1002/art.20991] [PMID: 15818689]
[19]
Gubrij IB, Martin SR, Pangle AK, Kurten R, Johnson LG. Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase. Hum Gene Ther 2014; 25(6): 498-505.
[http://dx.doi.org/10.1089/hum.2013.187] [PMID: 24512101]
[20]
Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002; 100(9): 3245-52.
[http://dx.doi.org/10.1182/blood-2002-01-0185] [PMID: 12384424]
[21]
Zhi X, Lin L, Yang S, et al. βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology 2015; 61(2): 598-612.
[http://dx.doi.org/10.1002/hep.27558] [PMID: 25307947]
[22]
Jiang X, Li H, Qiao H, Jiang H, Xu R, Sun X. Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci 2009; 100(11): 2226-33.
[http://dx.doi.org/10.1111/j.1349-7006.2009.01306.x] [PMID: 19709125]
[23]
Wang NQ, Zou J, Diao Y. Plasmid-mediated expression of kallistatin and its biological activity in lung cancer related cells. Yao Xue Xue Bao 2013; 48(3): 359-65.
[PMID: 23724648]
[24]
Wang G, Wang X, Huang X, et al. Inhibition of integrin beta3, a binding partner of kallistatin, leads to reduced viability, invasion and proliferation in nci-h446 cells. Cancer Cell Int 2016; 16: 90.
[http://dx.doi.org/10.1186/s12935-016-0365-7] [PMID: 27980455]
[25]
Song X, Zhang Y, Hou Z, et al. Adeno-associated virus serotype 9 mediated vascular endothelial growth factor gene overexpression in mdx mice. Exp Ther Med 2018; 15(2): 1825-30.
[http://dx.doi.org/10.3892/etm.2017.5610.] [PMID: 29434771]
[26]
Kotchey NM, Adachi K, Zahid M, et al. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol Ther 2011; 19(6): 1079-89.
[http://dx.doi.org/10.1038/mt.2011.3] [PMID: 21364543]
[27]
Pourshafie N, Lee PR, Chen KL, et al. Systemic delivery of microrna using recombinant adeno-associated virus serotype 9 to treat neuromuscular diseases in rodents. J Vis Exp 2018; 138: 55724.
[http://dx.doi.org/10.3791/55724] [PMID: 30148479]
[28]
Sun Z, Ma YT, Chen BD, Liu F. Recombinant adeno-associated virus serotype 9 with p65 ribozyme protects H9c2 cells from oxidative stress through inhibiting NF-κB signaling pathway. J Geriatr Cardiol 2014; 11(4): 311-5.
[http://dx.doi.org/10.11909/j.issn.1671-5411.2014.04.006.] [PMID: 25593580]
[29]
Matsuzaki Y, Konno A, Mukai R, et al. Transduction profile of the marmoset central nervous system using adeno-associated virus serotype 9 vectors. Mol Neurobiol 2017; 54(3): 1745-58.
[http://dx.doi.org/10.1007/s12035-016-9777-6] [PMID: 26884266]
[30]
Pfeifer C, Aneja MK, Hasenpusch G, Rudolph C. Adeno-associated virus serotype 9-mediated pulmonary transgene expression: effect of mouse strain, animal gender and lung inflammation. Gene Ther 2011; 18(11): 1034-42.
[http://dx.doi.org/10.1038/gt.2011.42] [PMID: 21512507]
[31]
Prystupa A, Kiciński P, Luchowska-Kocot D, et al. Factors influencing serum chemerin and kallistatin concentrations in patients with alcohol-induced liver cirrhosis. Ann Agric Environ Med 2019; 26(1): 143-7.
[http://dx.doi.org/10.26444/aaem/100536] [PMID: 30922045]
[32]
Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70(5): 3227-34.
[http://dx.doi.org/10.1128/JVI.70.5.3227-3234.1996] [PMID: 8627803]
[33]
Wang J, Xie J, Lu H, et al. Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci USA 2007; 104(32): 13104-9.
[http://dx.doi.org/10.1073/pnas.0702778104] [PMID: 17664425]
[34]
Salganik M, Aydemir F, Nam HJ, McKenna R, Agbandje-McKenna M, Muzyczka N. Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J Virol 2014; 88(2): 1071-9.
[http://dx.doi.org/10.1128/JVI.02093-13] [PMID: 24198419]
[35]
Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 2011; 19(6): 1058-69.
[http://dx.doi.org/10.1038/mt.2011.72] [PMID: 21487395]
[36]
Fathi E, Valipour B, Sanaat Z, Nozad Charoudeh H, Farahzadi R. Interleukin-6, -8, and tgf-beta secreted from mesenchymal stem cells show functional role in reduction of telomerase activity of leukemia cell via wnt5a/beta-catenin and p53 pathways. Adv Pharm Bull 2020; 10(2): 307-14.
[http://dx.doi.org/10.34172/apb.2020.037] [PMID: 32373501]
[37]
Minamino T, Miyauchi H, Yoshida T, Tateno K, Kunieda T, Komuro I. Vascular cell senescence and vascular aging. J Mol Cell Cardiol 2004; 36(2): 175-83.
[http://dx.doi.org/10.1016/j.yjmcc.2003.11.010] [PMID: 14871544]
[38]
Chao J, Guo Y, Chao L. Protective role of endogenous kallistatin in vascular injury and senescence by inhibiting oxidative stress and inflammation. Oxid Med Cell Longev 2018; 20184138560
[http://dx.doi.org/10.1155/2018/4138560]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy